Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2019-01
-
Unlike many forms of SNHL cCMV may be
2021-03-11

Unlike many forms of SNHL, cCMV may be treatable. The antiviral drug valganciclovir (VGCV) has been proposed to improve hearing, speech, and language outcomes associated with this infection [6]. A recent publication from the CASG (Collaborative Antiviral Study Group) reported that a six-month course
-
br Discussion The present results demonstrate that high
2021-03-11

Discussion The present results demonstrate that high dose estrogen–progestogen OC treatment produced impaired glucose tolerance and glucose tolerance was preserved during low dose estrogen–progestogen, high or low dose progestogen-only OC use. The study also shows that impaired glucose tolerance
-
br Disclosure statement br Acknowledgements This research wa
2021-03-11

Disclosure statement Acknowledgements This research was supported by grants from the National Institutes of Health, NS046400 and AG022971 (SD), and a fellowship from the Korea Research Foundation, KRF-2007-357-E00016 (YTK). The authors thank Dr. Barbara Crain for assistance with the immunologi
-
br Methods br Results br Discussion
2021-03-11

Methods Results Discussion The findings of this study indicate that an ET system including ET-1 and ET-2 as well as ET receptors are present in the retina and RPE/choroid, and are up-regulated by both hypertension and diabetes. Specifically, individual antagonism of the ETRA or ETRB deliver
-
br Materials and methods br Results and discussion
2021-03-11

Materials and methods Results and discussion Conclusions Codon-optimized MGSK-Lys-C was expressed at a high level in an optimized expression system as inclusion bodies. The Lys-C activity reached its maximum with about 9340 nkat/Lculture under standard (chemical) refolding conditions. The r
-
br Experimental Procedures br Author
2021-03-11

Experimental Procedures Author Contributions Acknowledgments Introduction The intestinal mucosal barrier surface is constantly exposed to food antigens, beneficial microbes, pathogens, and a multitude of other environmental stimuli (Turner, 2009). Innate lymphoid Topotecan HCl (ILCs) ar
-
HOIP s ability to build linear
2021-03-11

HOIP's ability to build linear Ub chains arises from a unique domain that follows directly after the RING2 domain, the linear ubiquitin chain-determining domain (LDD) (Fig. 1). Structures have revealed that the LDD is structurally integrated into RING2, creating a single RING2–LDD unit (Fig. 2D) [40
-
Although many GPCR heteromers have been identified using het
2021-03-11

Although many GPCR heteromers have been identified using heterologous cell lines, only very few fit all three criteria. This is mainly due to the difficulties to study these structures in native tissues because of the lack of sensitive and selective tools, not only capable of detecting in vivo evide
-
SANT-1 Herein in continuation of our interest in designing
2021-03-11

Herein, in continuation of our interest in designing new DNA photocleavage agents [18], we report the synthesis, characterization and DNA binding and cleaving properties of a novel compound: trans-N,N-dimethyl-10,11-di(pyridin-4-ium)-10,11-dihydro-9,12-dioxobenzo[e]phenanthrene tetrafluoroborate (1)
-
br Materials and methods br
2021-03-10

Materials and methods Results Discussion Intra-BNST injections of NOC-9 (at all doses) were able to produce freezing and anxiogenic-like effects. Freezing was observed immediately after the NO donor injection and lasted about 2–3min (data not shown). When exposed to the EPM 5min after intra
-
Other mutations in the SYNE region
2021-03-10

Other mutations in the SYNE1 3′ region (exons 81–85) have been implicated in an upper motor neuron disease, ARCA1 (Gros-Louis et al., 2007). The disease is characterized by progressive movement, coordination, and balance problems caused by disrupted Purkinje cell function and their impaired signalin
-
br Study br Study meta analyses
2021-03-10

Study 1 Study 2: meta-analyses Discussion Ten studies have examined the associations of 5-HTTLPR and COMT Val158Met with alexithymia. However, the findings were mixed. In this study, we found that neither the 5-HTTLPR nor COMT Val158Met is associated with alexithymia. The previous findings
-
br Results br Discussion Fetal development occurs under cond
2021-03-10

Results Discussion Fetal development occurs under conditions of low oxygen tension and steady maternal glucose such that physiologic systems including the pancreas are functionally poised in the prenatal state. Postnatally, oxidative metabolism becomes dominant and intermittent feeding exposes
-
The present study also showed that EP deficiency and EP
2021-03-10

The present study also showed that EP2 deficiency and EP4 antagonism significantly suppressed psoriatic SB-222200 in an imiquimod model. Notably, however, the combined EP2 deficiency and EP4 antagonism did not completely suppress ear swelling in this model, possibly because there is the IL-17–indep
-
adenosine 5 triphosphate disodium australia Importantly we o
2021-03-10

Importantly, we observed significantly the reduced myocardial infarct size, the improved left ventricular function and the inhibited fibrosis after I/R with oral GA-BH4 supplementation before ischemia (Fig. 1, Fig. 2, Fig. 3). Usually, there is a view that the antioxidation induced by reducing agent
15410 records 674/1028 page Previous Next First page 上5页 671672673674675 下5页 Last page